<DOC>
	<DOCNO>NCT00586807</DOCNO>
	<brief_summary>The metabolic response ulcerative colitis , include increase proteolysis lipolysis change energy expenditure , play significant role result malnutrition patient suffer . Tumor necrosis factor-alpha ( TNF-alpha ) , pro-inflammatory cytokine , find elevate child ulcerative colitis . TNF-alpha incriminate mechanism weight loss many different chronic disease , cause net protein lipid catabolism . Anti-TNF-alpha antibody ( infliximab ) proven effective therapy ulcerative colitis . The purpose study determine change protein lipid metabolism , well rest energy expenditure , therapy anti-TNF-alpha antibody ( infliximab ) child ulcerative colitis . Performing study well define change nutrition status observe child follow remission active ulcerative colitis , potentially lead change medical nutritional management child</brief_summary>
	<brief_title>Metabolic Response Infliximab Pediatric Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Male female child age six eighteen year age Endoscopic histologic evidence ulcerative colitis Active ulcerative colitis determine primary pediatric gastroenterologist require antitumor necrosis factoralpha antibody ( infliximab ) therapy Colitis symptom score â‰¥2 Screening laboratory test meet follow criterion ( obtain within 4 week enrollment ) : 1 . Hemoglobin &gt; 8.0 g/dL 2 . White blood cell count &gt; 3.5 x 109/L 3 . Neutrophils &gt; 1.5 x 109/L 4 . Platelets &gt; 100 x 109/L 5 . Aspartate aminotransferase , alanine aminotransferase , alkaline phosphatase level within 3 time upper limit normal . 6 . PPD skin test skin induration &lt; 5 mm . 7 . Signed write consent parent/legal guardian assent child obtain prior enrollment . Female subject pregnant , nursing , plan pregnancy . Concomitant diagnosis history congestive heart failure . Serious infection 3 month prior enrollment . History prior current active latent tuberculosis . Immune deficiency syndrome , include document human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) . History systemic lupus erythematosus . A transplanted organ . Known malignancy history malignancy within 5 year enrollment . History demyelinate disease . History substance abuse . History diabetes mellitus . Poor tolerability venipuncture lack venous access study period . A live virus vaccination within 3 month enrollment . Prior history infliximab infusion therapeutic agent target reduce tumor necrosis factoralpha ( TNFalpha ) . Hypersensitivity murine proteins component product . Inability comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Ulcerative colitis</keyword>
	<keyword>pediatrics</keyword>
	<keyword>UC</keyword>
	<keyword>protein metabolism</keyword>
	<keyword>energy expenditure</keyword>
</DOC>